Systemic Targeted Alpha Therapy for Advanced Colorectal Cancer using Lead-203/Lead-212 PRIT
Official title: Systemic Theranostic 203Pb/212Pb Alpha-Radioimmunotherapy for Advanced Colorectal Cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-11433948 · Data updated 2026-11-12
A new therapy approach uses alpha-emitting radioisotopes paired for imaging and treatment to target colorectal cancer in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $724,256 |
| NIH project number | 1R01CA317908-01 |
| Project ID | NIH-11433948 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with advanced colorectal cancer expressing GPA33 may be eligible for future trials once the therapy advances to clinical testing.
✕Less likely to help
Patients without GPA33 expression or those unable to tolerate antibody-based therapies may not benefit.
What this research studies
This project aims to create a targeted radioimmunotherapy for advanced colorectal cancer by using a GPA33-targeted antibody combined with a lead-203/lead-212 theranostic pair. Researchers will design and test novel chelators and bispecific antibodies to optimize delivery, stability, and tumor uptake of the therapeutic agent. The goal is to achieve high tumor radiation doses while keeping blood and kidney exposure within safe limits, potentially allowing outpatient treatment. The work includes in vitro testing on GPA33-expressing cancer cells and preclinical assessments to identify a lead candidate for future clinical testing.
Why it matters
Potential benefit: If successful, this therapy could deliver effective tumor kill with manageable toxicity and enable outpatient treatment for advanced colorectal cancer.
How similar studies have gone: Previous work with radioimmunotherapies and targeted alpha therapies shows promise; this project explores an enhanced PRIT approach with novel chelators and bispecific antibodies.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Cheal, Sarah Marie — Weill Medical Coll of Cornell Univ
- Study coordinator: Cheal, Sarah Marie
Related research
Other NIH-funded projects on the same topics.
-
Improving colorectal cancer screening and follow-up care.
This study is working to help more people get screened for colorectal cancer and receive the follow-up care they need, especially those who haven't been screened much before, so that everyone can have better access to important health checks and improve their overall health.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
Ceramides and how they affect metabolism and colorectal cancer in adults
A study in adults with obesity-related health issues will explore how a fat-related molecule called ceramide influences metabolic problems and colorectal cancer risk.
-
Automated point-of-care DNA methylation test for colorectal cancer in LMICs
A fast, affordable blood test using DNA markers to help identify people at higher risk of colorectal cancer in low- and middle-income countries.
-
Rewiring Colorectal Cancer to Harness Therapeutic Hyperactivation
A Yale team is exploring brain-storming new ways to treat colorectal cancer by safely boosting certain cancer signaling pathways to kill cancer cells and by reshaping cancer cell states to improve responses to existing therapies.
-
Comparative modeling to guide colorectal cancer screening and care
A researcher team will use computer models to study how access to care, risk, and new screening options affect colorectal cancer outcomes and costs for adults in the US.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.